prodrugin
Prodrug is a type of pharmaceutical compound designed to be converted into an active drug within the body. It is a teichoic acid drug and the first such drug to enter human clinical trials.
Prodrugs were first introduced in the mid-1990s, as a way to improve the bioavailability of lipophilic drugs
The conversion of a prodrug into an active drug is typically catalyzed by an enzyme in the
Prodrugs have been studied for a wide range of conditions, including cancer, infections, and inflammatory diseases.
The first prodrug to enter human clinical trials was lipoxygenase inhibitor orrikil, however it was withdrawn